Recent recommendations on bisphosphonate-associated osteonecrosis of the jaw.
There is increasing awareness of the importance of osteonecrosis of the jaw developing in patients taking bisphosphonates. A recent working party of the American Society for Bone and Mineral Research has developed recommendations on the prevention and treatment of this condition which dentists will find useful.


CONCLUSIONS
As bisphosphonates are now being used widely in the treatment of several conditions including osteoporosis, Paget's disease and metastatic malignancy, dentists should be able to recognize osteonecrosis of the jaw and how it is managed.
Arrain
Yazdana
Y
University of Birmingham School of Dentistry, St Chad's Queensway, Birmingham B4 6NN.
Masud
Tahir
T
D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000517:prevention & control; D010020:Osteonecrosis / Q000139:chemically induced* / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D009626:Terminology as Topic
D050071:Bone Density Conservation Agents; D004164:Diphosphonates